Annexon Biosciences

7 articles with Annexon Biosciences

• 

  BioSpace Movers and Shakers, July 12

  7/12/2019

  Biotech and pharma companies strengthen their leadership teams with new appointments.

• Annexon Biosciences Expands Senior Leadership as it Advances its Novel Complement Approach to Autoimmune and Neurodegenerative Disorders

  7/9/2019

  Sanjay Keswani, MBBS, BSc, FRCP, Chief Medical Officer Jennifer Lew, Chief Financial Officer Lesley Stolz, PhD, Chief Business Officer

• 

  Companies Note Collaborations, Financing and Clinical Trial Success

  12/26/2018

  With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.

• Annexon Biosciences Closes $75 Million Financing

  12/19/2018

  Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing.

• Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor

  6/12/2018

  BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.

• Annexon Appoints Bill Young As Chairman And Adds Tom Wiggans To Board Of Directors

  3/9/2017

• Bay Area Startup Annexon Banks $44 Million Series B

  6/23/2016